Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany. more
Time Frame | AFMD | Sector | S&P500 |
---|---|---|---|
1-Week Return | -45.87% | -3.35% | -2.97% |
1-Month Return | -60.67% | -3.49% | -0.66% |
3-Month Return | -70.2% | -12.6% | 2.71% |
6-Month Return | -80% | -6.91% | 7.21% |
1-Year Return | -70.5% | 1.19% | 23.04% |
3-Year Return | -97.92% | -0.21% | 28.43% |
5-Year Return | -95.69% | 33.09% | 82.88% |
10-Year Return | -98.07% | 93.55% | 184.63% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 21.39M | 28.36M | 40.37M | 41.35M | 8.28M | [{"date":"2019-12-31","value":51.73,"profit":true},{"date":"2020-12-31","value":68.58,"profit":true},{"date":"2021-12-31","value":97.61,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":20.01,"profit":true}] |
Cost of Revenue | 1.55M | - | - | - | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Profit | 21.39M | 28.36M | 40.37M | 41.35M | 8.28M | [{"date":"2019-12-31","value":51.73,"profit":true},{"date":"2020-12-31","value":68.58,"profit":true},{"date":"2021-12-31","value":97.61,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":20.01,"profit":true}] |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 54.04M | 63.70M | 105.71M | 130.89M | 114.94M | [{"date":"2019-12-31","value":41.28,"profit":true},{"date":"2020-12-31","value":48.67,"profit":true},{"date":"2021-12-31","value":80.76,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":87.81,"profit":true}] |
Operating Income | (32.38M) | (34.72M) | (64.03M) | (88.12M) | (106.66M) | [{"date":"2019-12-31","value":-3237600000,"profit":false},{"date":"2020-12-31","value":-3471800000,"profit":false},{"date":"2021-12-31","value":-6403000000,"profit":false},{"date":"2022-12-31","value":-8811900000,"profit":false},{"date":"2023-12-31","value":-10666100000,"profit":false}] |
Total Non-Operating Income/Expense | 205.00K | (13.29M) | 5.38M | 4.23M | 964.00K | [{"date":"2019-12-31","value":3.81,"profit":true},{"date":"2020-12-31","value":-247.01,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":78.67,"profit":true},{"date":"2023-12-31","value":17.91,"profit":true}] |
Pre-Tax Income | (32.36M) | (41.37M) | (57.52M) | (86.00M) | (105.94M) | [{"date":"2019-12-31","value":-3236100000,"profit":false},{"date":"2020-12-31","value":-4136500000,"profit":false},{"date":"2021-12-31","value":-5752100000,"profit":false},{"date":"2022-12-31","value":-8600200000,"profit":false},{"date":"2023-12-31","value":-10593500000,"profit":false}] |
Income Taxes | 4.00K | 1.00K | 2.00K | 2.00K | 3.00K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":25,"profit":true},{"date":"2021-12-31","value":50,"profit":true},{"date":"2022-12-31","value":50,"profit":true},{"date":"2023-12-31","value":75,"profit":true}] |
Income After Taxes | (32.37M) | (41.37M) | (57.52M) | (86.00M) | (105.94M) | [{"date":"2019-12-31","value":-3236500000,"profit":false},{"date":"2020-12-31","value":-4136600000,"profit":false},{"date":"2021-12-31","value":-5752300000,"profit":false},{"date":"2022-12-31","value":-8600400000,"profit":false},{"date":"2023-12-31","value":-10593800000,"profit":false}] |
Income From Continuous Operations | (32.37M) | (41.37M) | (57.52M) | (86.00M) | (105.94M) | [{"date":"2019-12-31","value":-3236500000,"profit":false},{"date":"2020-12-31","value":-4136600000,"profit":false},{"date":"2021-12-31","value":-5752300000,"profit":false},{"date":"2022-12-31","value":-8600400000,"profit":false},{"date":"2023-12-31","value":-10593800000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (32.37M) | (41.37M) | (57.52M) | (86.00M) | (105.94M) | [{"date":"2019-12-31","value":-3236500000,"profit":false},{"date":"2020-12-31","value":-4136600000,"profit":false},{"date":"2021-12-31","value":-5752300000,"profit":false},{"date":"2022-12-31","value":-8600400000,"profit":false},{"date":"2023-12-31","value":-10593800000,"profit":false}] |
EPS (Diluted) | (0.50) | (0.55) | (0.49) | (0.60) | (1.92) | [{"date":"2019-12-31","value":-50,"profit":false},{"date":"2020-12-31","value":-55,"profit":false},{"date":"2021-12-31","value":-49,"profit":false},{"date":"2022-12-31","value":-60,"profit":false},{"date":"2023-12-31","value":-192,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
AFMD | |
---|---|
Cash Ratio | 1.49 |
Current Ratio | 1.93 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
AFMD | |
---|---|
ROA (LTM) | -49.31% |
ROE (LTM) | -124.08% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
AFMD | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.57 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.43 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
AFMD | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 2.78 |
P/B | 1.14 |
Price/FCF | NM |
EV/R | 8.70 |
EV/Ebitda | 1.13 |
PEG | NM |
Affimed NV (AFMD) share price today is $1.18
Yes, Indians can buy shares of Affimed NV (AFMD) on Vested. To buy Affimed NV from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in AFMD stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Affimed NV (AFMD) via the Vested app. You can start investing in Affimed NV (AFMD) with a minimum investment of $1.
You can invest in shares of Affimed NV (AFMD) via Vested in three simple steps:
The 52-week high price of Affimed NV (AFMD) is $8.95. The 52-week low price of Affimed NV (AFMD) is $1.15.
The price-to-earnings (P/E) ratio of Affimed NV (AFMD) is
The price-to-book (P/B) ratio of Affimed NV (AFMD) is 1.14
The dividend yield of Affimed NV (AFMD) is 0.00%
The market capitalization of Affimed NV (AFMD) is $20.65M
The stock symbol (or ticker) of Affimed NV is AFMD